Sangui Biotech International Stock Price Prediction

SGBI Stock  USD 0  0.00  0.00%   
As of 29th of March 2024, the relative strength index (RSI) of Sangui Biotech's share price is approaching 35. This usually implies that the pink sheet is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Sangui Biotech, making its price go up or down.

Oversold Vs Overbought

35

 
Oversold
 
Overbought
Sangui Biotech Inter stock price prediction is an act of determining the future value of Sangui Biotech shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Sangui Biotech's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Sangui Biotech and does not consider all of the tangible or intangible factors available from Sangui Biotech's fundamental data. We analyze noise-free headlines and recent hype associated with Sangui Biotech International, which may create opportunities for some arbitrage if properly timed.
It is a matter of debate whether pink sheet price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Sangui Biotech based on different types of headlines from major news networks to social media. The Sangui stock price prediction module provides an analysis of price elasticity to changes in media outlook on Sangui Biotech over a specific investment horizon. Using Sangui Biotech hype-based prediction, you can estimate the value of Sangui Biotech International from the perspective of Sangui Biotech response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in Sangui Biotech. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Sangui Biotech to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Sangui because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Sangui Biotech after-hype prediction price

    
  USD 0.001859  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Sangui Biotech Basic Forecasting Models to cross-verify your projections.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Sangui Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.00011.54
Details
Naive
Forecast
LowNextHigh
0.000035011.54
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Sangui Biotech. Your research has to be compared to or analyzed against Sangui Biotech's peers to derive any actionable benefits. When done correctly, Sangui Biotech's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Sangui Biotech Inter.

Sangui Biotech After-Hype Price Prediction Density Analysis

As far as predicting the price of Sangui Biotech at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Sangui Biotech or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Sangui Biotech, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Sangui Biotech Estimiated After-Hype Price Volatility

In the context of predicting Sangui Biotech's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Sangui Biotech's historical news coverage. Sangui Biotech's after-hype downside and upside margins for the prediction period are 0.00 and 11.54, respectively. We have considered Sangui Biotech's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
0
0
After-hype Price
11.54
Upside
Sangui Biotech is out of control at this time. Analysis and calculation of next after-hype price of Sangui Biotech Inter is based on 3 months time horizon.

Sangui Biotech Pink Sheet Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Sangui Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sangui Biotech backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Sangui Biotech, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.03 
11.54
 0.00  
  0.02 
0 Events / Month
4 Events / Month
Within a week
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0
0
23.91 
0.00  
Notes

Sangui Biotech Hype Timeline

Sangui Biotech Inter is at this time traded for 0. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.02. Sangui is forecasted to increase in value after the next headline, with the price projected to jump to 0.001859 or above. The average volatility of media hype impact on the company the price is insignificant. The price growth on the next news is estimated to be 23.91%, whereas the daily expected return is at this time at -0.03%. The volatility of related hype on Sangui Biotech is about 1811.21%, with the expected price after the next announcement by competition of 0.02. The company currently holds 48.9 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Sangui Biotech Inter has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Sangui Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Sangui Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sangui Biotech Inter sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sangui to invest in growth at high rates of return. When we think about Sangui Biotech's use of debt, we should always consider it together with cash and equity.Given the investment horizon of 90 days the next forecasted press release will be within a week.
Check out Sangui Biotech Basic Forecasting Models to cross-verify your projections.

Sangui Biotech Related Hype Analysis

Having access to credible news sources related to Sangui Biotech's direct competition is more important than ever and may enhance your ability to predict Sangui Biotech's future price movements. Getting to know how Sangui Biotech rivals react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Sangui Biotech may potentially react to the hype associated with one of its peers.

Sangui Biotech Additional Predictive Modules

Most predictive techniques to examine Sangui price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Sangui using various technical indicators. When you analyze Sangui charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Sangui Biotech Predictive Indicators

The successful prediction of Sangui Biotech stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Sangui Biotech International, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Sangui Biotech based on analysis of Sangui Biotech hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Sangui Biotech's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Sangui Biotech's related companies.

Story Coverage note for Sangui Biotech

The number of cover stories for Sangui Biotech depends on current market conditions and Sangui Biotech's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Sangui Biotech is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Sangui Biotech's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Other Macroaxis Stories

Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios

Sangui Biotech Short Properties

Sangui Biotech's future price predictability will typically decrease when Sangui Biotech's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Sangui Biotech International often depends not only on the future outlook of the potential Sangui Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Sangui Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding204.2 M
Cash And Short Term Investments30.5 K
Check out Sangui Biotech Basic Forecasting Models to cross-verify your projections.
Note that the Sangui Biotech Inter information on this page should be used as a complementary analysis to other Sangui Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for Sangui Pink Sheet analysis

When running Sangui Biotech's price analysis, check to measure Sangui Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangui Biotech is operating at the current time. Most of Sangui Biotech's value examination focuses on studying past and present price action to predict the probability of Sangui Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangui Biotech's price. Additionally, you may evaluate how the addition of Sangui Biotech to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Please note, there is a significant difference between Sangui Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangui Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangui Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.